Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis
| Main Author: | |
|---|---|
| Publication Date: | 2024 |
| Other Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | eng |
| Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| Download full: | http://hdl.handle.net/10362/170441 |
Summary: | Funding Information: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © 2024 The Authors |
| id |
RCAP_ce72fb03afc1f0096b7c9305ce6b484e |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/170441 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository_id_str |
https://opendoar.ac.uk/repository/7160 |
| spelling |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritisrelationship with the reason for withdrawal from the previous treatmentEpidemiologyPsoriatic arthritisTNF-inhibitorsTreatment withdrawalRheumatologyFunding Information: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © 2024 The AuthorsObjective: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. Methods: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted Cox regression analyses and Chi-squared test, respectively). Results: We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67–70%) and 66% (64–68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi). Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi. Conclusion: Two-thirds of patients remained on TNFi at 12 months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6 months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.Comprehensive Health Research Centre (CHRC) - Pólo ENSPCentro de Investigação em Saúde Pública (CISP/PHRC)Escola Nacional de Saúde Pública (ENSP)RUNØrnbjerg, Lykke MidtbøllBrahe, Cecilie HeegaardLinde, LouiseJacobsson, LennartNissen, Michael J.Kristianslund, Eirik KlamiSantos, Maria JoséNordström, DanRotar, ZigaGudbjornsson, BjornOnen, FatosCodreanu, CatalinLindström, UlfMöller, BurkhardKvien, Tore K.Barcelos, AnabelaEklund, Kari K.Tomšič, MatijaLove, Thorvardur JonCan, GercekIonescu, RuxandraLoft, Anne GitteMann, HermanPavelka, Karelvan de Sande, Marleenvan der Horst-Bruinsma, I. E.Suarez, Manuel PomboSánchez-Piedra, CarlosMacfarlane, Gary J.Iannone, FlorenzoMichelsen, BrigitteHyldstrup, Lise HejlKrogh, Niels SteenØstergaard, MikkelHetland, Merete Lund2024-08-08T22:16:06Z2024-072024-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/170441eng1297-319XPURE: 97358952https://doi.org/10.1016/j.jbspin.2024.105729info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-09-09T01:40:12Zoai:run.unl.pt:10362/170441Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T18:48:55.130240Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
| dc.title.none.fl_str_mv |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis relationship with the reason for withdrawal from the previous treatment |
| title |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis |
| spellingShingle |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis Ørnbjerg, Lykke Midtbøll Epidemiology Psoriatic arthritis TNF-inhibitors Treatment withdrawal Rheumatology |
| title_short |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis |
| title_full |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis |
| title_fullStr |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis |
| title_full_unstemmed |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis |
| title_sort |
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis |
| author |
Ørnbjerg, Lykke Midtbøll |
| author_facet |
Ørnbjerg, Lykke Midtbøll Brahe, Cecilie Heegaard Linde, Louise Jacobsson, Lennart Nissen, Michael J. Kristianslund, Eirik Klami Santos, Maria José Nordström, Dan Rotar, Ziga Gudbjornsson, Bjorn Onen, Fatos Codreanu, Catalin Lindström, Ulf Möller, Burkhard Kvien, Tore K. Barcelos, Anabela Eklund, Kari K. Tomšič, Matija Love, Thorvardur Jon Can, Gercek Ionescu, Ruxandra Loft, Anne Gitte Mann, Herman Pavelka, Karel van de Sande, Marleen van der Horst-Bruinsma, I. E. Suarez, Manuel Pombo Sánchez-Piedra, Carlos Macfarlane, Gary J. Iannone, Florenzo Michelsen, Brigitte Hyldstrup, Lise Hejl Krogh, Niels Steen Østergaard, Mikkel Hetland, Merete Lund |
| author_role |
author |
| author2 |
Brahe, Cecilie Heegaard Linde, Louise Jacobsson, Lennart Nissen, Michael J. Kristianslund, Eirik Klami Santos, Maria José Nordström, Dan Rotar, Ziga Gudbjornsson, Bjorn Onen, Fatos Codreanu, Catalin Lindström, Ulf Möller, Burkhard Kvien, Tore K. Barcelos, Anabela Eklund, Kari K. Tomšič, Matija Love, Thorvardur Jon Can, Gercek Ionescu, Ruxandra Loft, Anne Gitte Mann, Herman Pavelka, Karel van de Sande, Marleen van der Horst-Bruinsma, I. E. Suarez, Manuel Pombo Sánchez-Piedra, Carlos Macfarlane, Gary J. Iannone, Florenzo Michelsen, Brigitte Hyldstrup, Lise Hejl Krogh, Niels Steen Østergaard, Mikkel Hetland, Merete Lund |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Comprehensive Health Research Centre (CHRC) - Pólo ENSP Centro de Investigação em Saúde Pública (CISP/PHRC) Escola Nacional de Saúde Pública (ENSP) RUN |
| dc.contributor.author.fl_str_mv |
Ørnbjerg, Lykke Midtbøll Brahe, Cecilie Heegaard Linde, Louise Jacobsson, Lennart Nissen, Michael J. Kristianslund, Eirik Klami Santos, Maria José Nordström, Dan Rotar, Ziga Gudbjornsson, Bjorn Onen, Fatos Codreanu, Catalin Lindström, Ulf Möller, Burkhard Kvien, Tore K. Barcelos, Anabela Eklund, Kari K. Tomšič, Matija Love, Thorvardur Jon Can, Gercek Ionescu, Ruxandra Loft, Anne Gitte Mann, Herman Pavelka, Karel van de Sande, Marleen van der Horst-Bruinsma, I. E. Suarez, Manuel Pombo Sánchez-Piedra, Carlos Macfarlane, Gary J. Iannone, Florenzo Michelsen, Brigitte Hyldstrup, Lise Hejl Krogh, Niels Steen Østergaard, Mikkel Hetland, Merete Lund |
| dc.subject.por.fl_str_mv |
Epidemiology Psoriatic arthritis TNF-inhibitors Treatment withdrawal Rheumatology |
| topic |
Epidemiology Psoriatic arthritis TNF-inhibitors Treatment withdrawal Rheumatology |
| description |
Funding Information: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © 2024 The Authors |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-08-08T22:16:06Z 2024-07 2024-07-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/170441 |
| url |
http://hdl.handle.net/10362/170441 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
1297-319X PURE: 97358952 https://doi.org/10.1016/j.jbspin.2024.105729 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
| instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| repository.mail.fl_str_mv |
info@rcaap.pt |
| _version_ |
1833597680323919872 |